Opportunity

SAM #SP4701-26-Q-0129

Renewal of Medi-Span Electronic Drug File (MED-File) v2 Data License Subscription for DLA Troop Support Medical Directorate

Buyer

DLA DCSO Philadelphia

Posted

September 01, 2026

Respond By

September 08, 2026

Identifier

SP4701-26-Q-0129

NAICS

541690, 511210

The Defense Logistics Agency (DLA) Troop Support Medical Directorate is seeking to renew its subscription for the Medi-Span Electronic Drug File (MED-File) v2, a critical pharmaceutical data feed used in Defense Medical Logistics Standard Support-Wholesale (DMLSS-W) applications. - Government Buyer: - Defense Logistics Agency (DLA) - Sub-agency: DLA Troop Support Medical Directorate - Office: DLA Contracting Services Office Philadelphia - OEM Highlight: - Wolters Kluwer Health is the sole OEM and provider of the Medi-Span MED-File product - Products/Services Requested: - Renewal of Medi-Span Electronic Drug File (MED-File) v2 data license subscription - Five total annual units (one base year plus four option years) - No specific part numbers provided - Notable Requirements: - The MED-File data feed is essential for pharmaceutical pricing, catalog build processes, and DMLSS-W applications - The contract is firm fixed price and includes compliance with trafficking in persons regulations - Quantities: - One subscription per year for five years (base plus four option years)

Description

:  The DLA Troop Support Medical Directorate has a need to renew the data license subscription for the Medi-Span Electronic Drug File (MED-File) ™v2, formerly known as (f/k/a) the Master Drug Data Base (MDDB) ™. This requirement is a product of Medi-Span®, which is a part of Wolters Kluwer Health and is a critical data feed for the Medical Directorate’s Product Data Bank (PDB) and Medical Master Catalog (MMC) build processes. The Average Wholesale Price (AWP) provided in the MED-File is a critical component in all the referenced DMLSS-W applications used to negotiate the most favorable pharmaceutical pricing available with DoD suppliers and acquire pharmaceutical products under the best federal pricing

View original listing